NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment

Obinutuzumab (OBZ) shows stronger antibody-dependent cell cytotoxicity (ADCC) compared to rituximab and improved clinical activity for treating certain CD20(+) neoplasia. However, the efficacy of monoclonal antibody (mAb) as a monotherapy is limited. Natural Killer (NK) cells are mediators of ADCC....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Vo, Dang-Nghiem, Alexia, Catherine, Allende-Vega, Nerea, Morschhauser, Franck, Houot, Roch, Menard, Cedric, Tarte, Karin, Cartron, Guillaume, Villalba, Martin
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889292/
https://ncbi.nlm.nih.gov/pubmed/29632722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1409322
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars